[A21-61] Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide und dexamethasone) - Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2021
Project no.:
A21-61
Commission:
Commission awarded on 12.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-60 | Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-124 | Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Addendum to Commission A21-61 | Commission completed |
Federal Joint Committee (G-BA)
04-11-2021 A G-BA decision was published.